C-Reactive Protein Testing

Global C-Reactive Protein Testing Market to Reach US$6.3 Billion by 2032

The global market for C-Reactive Protein Testing estimated at US$5.2 Billion in the year 2025, is expected to reach US$6.3 Billion by 2032, growing at a CAGR of 2.9% over the analysis period 2025-2032. Immunoturbidimetric Assay Type, one of the segments analyzed in the report, is expected to record a 2.1% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the ELISA Type segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 2.8% CAGR

The C-Reactive Protein Testing market in the U.S. is estimated at US$1.5 Billion in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2032 trailing a CAGR of 2.8% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global C-Reactive Protein Testing Market - Key Trends and Drivers Summarized

Beyond Inflammation: What Can C-Reactive Protein Testing Really Tell Us?

C-reactive protein (CRP) testing is a widely used diagnostic tool designed to measure the level of CRP in the blood, a protein produced by the liver in response to inflammation. The presence of CRP is associated with a variety of conditions, from acute infections to chronic diseases and autoimmune disorders. By measuring CRP levels, healthcare providers can assess if there is an inflammation in the body, determine its severity, and monitor the effectiveness of treatment. This test is particularly valuable because it can help distinguish between bacterial infections, which typically cause a higher CRP elevation, and viral infections, alongside guiding therapy in chronic inflammatory conditions like rheumatoid arthritis and Crohn`s disease.

How Is Technology Enhancing CRP Testing Accuracy and Accessibility?

The accuracy and utility of CRP testing have significantly improved with advancements in medical technology. Modern CRP tests can deliver results in a matter of minutes, allowing for rapid clinical decision-making. Point-of-care CRP testing devices, which can be used directly at the patient’s bedside or in the doctor`s office, are particularly revolutionary. They eliminate the need to send samples to a lab and reduce the waiting time for results. Moreover, recent developments in microfluidics and biosensing technologies have led to the creation of even smaller, more sensitive CRP testing devices that require only a tiny blood sample, making the test less invasive and more comfortable for patients.

What Challenges Are Faced in the Implementation of CRP Testing?

Despite its benefits, the implementation of CRP testing faces certain challenges. One of the primary concerns is the potential for overuse or misuse of the test, particularly in situations where CRP levels may not provide definitive diagnostic information. Misinterpretation of CRP results can lead to unnecessary treatments, such as the inappropriate use of antibiotics for viral infections. Additionally, while point-of-care CRP testing offers convenience, ensuring the accuracy and reliability of these devices across all healthcare settings is critical but challenging. Training healthcare providers to understand and integrate CRP test results effectively into the clinical context is also essential to maximize the test`s benefits and avoid potential drawbacks.

What Key Factors Are Fueling the Expansion of the CRP Testing Market?

The growth in the C-Reactive Protein testing market is driven by several factors. The rising prevalence of inflammatory diseases such as cardiovascular disorders, rheumatoid arthritis, and inflammatory bowel disease has led to an increased demand for effective diagnostic and monitoring tools like CRP testing. Growing awareness among physicians and patients about the importance of inflammation and its role in various health conditions also contributes to this trend. Additionally, the expansion of point-of-care diagnostics and the increasing availability of affordable and rapid CRP testing devices have made these tests more accessible to a broader segment of the population. As health systems continue to emphasize preventive care and early intervention, CRP testing is positioned as a valuable tool in the medical arsenal, promoting its adoption and market growth across diverse healthcare environments.

SCOPE OF STUDY:

The report analyzes the C-Reactive Protein Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Disease Type (Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Other Disease Types); Assay Type (Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Other Assay Types); End-Use (Hospitals, Laboratories, Clinics, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

SELECT PLAYERS -

• Abaxis, Inc.
• Abbott Laboratories
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Laboratory Corporation of America Holdings (LabCorp)
• Merck KgaA
• Quest Diagnostics, Inc.
• Randox Laboratories Ltd.
• Siemens Healthineers AG
• Thermo Fisher Scientific, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more